ACETHealthcare · BiotechnologyThe 6 Wall Street analysts covering Adicet Bio, Inc. hold a median 12-month price target of $23 — +144.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 21 Aug 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Adicet Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (78): Reported profit is backed by cash, and the company is not expanding recklessly.
Value (6): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ACET, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +144.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Aug 2026 | Guggenheim | Maintains | Buy | $100 → $90 |
| 5 May 2026 | Jefferies | Assumes | Buy | $8.00 → $19 |
| 23 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Mar 2026 | Guggenheim | Maintains | Buy | — |
| 21 Jan 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 6 Jan 2026 | Canaccord Genuity | Maintains | Buy | — |
| 7 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Oct 2025 | Guggenheim | Maintains | Buy | — |
| 19 Sept 2025 | Guggenheim | Reiterates | Buy | — |
| 23 July 2025 | HC Wainwright & Co. | Assumes | Buy | $4.00 |
| 21 Mar 2025 | Guggenheim | Reiterates | Buy | — |
| 7 Mar 2025 | Citizens Capital Markets | Reiterates | Market Perform | — |
| 7 Mar 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 27 Feb 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 6 Feb 2025 | JMP Securities | Reiterates | Market Perform | — |
| 5 Feb 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 19 Dec 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 18 Nov 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 16 Oct 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 30 Sept 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ACET appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 80% of US stocks
Cheaper than 78% of US stocks
Cheaper than 60% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 16% of US stocks
Higher than 10% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Adicet Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research compared the year-to-date performance of Adicet Bio, Inc. (ACET) and Agilent Technologies (A) against their sector. The article examines how the two medical stocks have fared relative to the broader sector so far this year.
Why it matters — ACET watchers would care because the piece provides a sector-relative performance comparison for the stock so far this year.
Seeking Alpha notes that Adicet Bio's allogeneic gamma delta CAR-T platform for autoimmune diseases is trading below cash value, with early prula-cel data in lupus nephritis showing a 50% complete renal response and clean safety. A pivotal readout on 22 patients is expected in Q3 2026.
Why it matters — A shareholder would care because the upcoming Q3 2026 readout is a binary catalyst that will test whether prula-cel's durability and long-term remission can support the curative CAR-T thesis for autoimmune diseases.
Zacks Investment Research notes that Wall Street analysts' consensus price target for Adicet Bio (ACET) implies an upside potential of roughly 301.6%. The article observes that while such consensus price targets have limited empirical reliability, an upward trend in earnings estimate revisions may signal near-term upside for the stock.
Why it matters — ACET watchers would care because the article highlights a high consensus price target and a positive trend in earnings estimate revisions, both of which point to analyst optimism about the company.
Adicet Bio expects to report clinical data this quarter for its lead autoimmune program, ADI-001 (prula-cel), including results in lupus nephritis and systemic lupus erythematosus. CEO Chen Schor shared this outlook at the 46th Annual Canaccord Genuity Growth Conference.
Why it matters — ACET watchers will be monitoring the upcoming ADI-001 data release as a key development milestone for the company's lead autoimmune therapy program.
Zacks Investment Research upgraded Adicet Bio (ACET) to a Zacks Rank #2 (Buy), citing growing optimism about the company's earnings prospects. The report notes this rating could influence near-term stock movement.
Why it matters — The rating upgrade reflects a more favorable assessment of Adicet Bio's earnings outlook, which is relevant for shareholders monitoring the company's prospects.
The 6 Wall Street analysts covering Adicet Bio, Inc. have a median 12-month price target of $23, with estimates ranging from $18 to $90. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering Adicet Bio, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Adicet Bio, Inc. 43 out of 100 across roughly 4,600 US stocks as at 21 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 21 Aug 2026, Adicet Bio, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (78 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +144.8% from the last close, and Ticker Nerd's factor model ranks Adicet Bio, Inc. 43 out of 100 as at 21 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Adicet Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACET are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $90 over the next 12 months.
Adicet Bio, Inc. returned -15.9% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Adicet Bio, Inc. is a clinical-stage biotechnology company specializing in the discovery and development of allogeneic gamma delta T cell therapies.
The most recent item we track (Zacks Investment Research, 18 Aug 2026): "Are Medical Stocks Lagging Adicet Bio (ACET) This Year?". Zacks Investment Research compared the year-to-date performance of Adicet Bio, Inc. (ACET) and Agilent Technologies (A) against their sector. The article examines how the two medical stocks have fared relative to the broader sector so far this year.
Adicet Bio, Inc. is a clinical-stage biotechnology company specializing in the discovery and development of allogeneic gamma delta T cell therapies. These off-the-shelf treatments harness gamma delta T cells to target and eliminate cancer cells through multiple mechanisms, while also facilitating innate and adaptive immune responses, and providing B-cell depletion for immune reset in autoimmune diseases. The company's novel platform emphasizes key advantages such as precise novel targeting, effective tissue homing, optimal drug exposure, and immediate availability on demand, distinguishing it from autologous therapies. Adicet Bio, Inc. focuses on delivering first-in-class solutions for patients battling cancer and autoimmune conditions, supported by a collaborative team driving innovation in the cell therapy sector. With operations in Redwood City, California; Boston, Massachusetts; and Shanghai, China, the company advances cutting-edge science toward curative potential in oncology and immunology markets.
CEO Mr. Chen Schor BA, CPA, M.B.A. · 102 employees · United States · https://www.adicetbio.com